









Atlas Genet Cytogenet Oncol Haematol. 2008;12(3)  223 
Atlas of Genetics and Cytogenetics 
in Oncology and Haematology                         
                         OPEN ACCESS JOURNAL AT INIST-CNRS 
MUC16 (mucin 16, cell surface associated) 
Shantibhusan Senapati, Moorthy P Ponnusamy, Ajay P Singh, Maneesh Jain, Surinder K Batra 
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, 985870 
Nebraska Medical Center, Durham Research center 7005, Omaha, NE 68198-5870, USA 
Published in Atlas Database: October 2007 
Online updated version: http://AtlasGeneticsOncology.org/Genes/MUC16ID41455ch19q13.html  
DOI: 10.4267/2042/38525 
This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. 




Other names: CA125; FLJ14303; Mucin-16 
Location: 19p13.2 
Note: MUC16 belongs to the subgroup of the 
membrane-anchored mucin. It is a type-1 glycopotein 
with heavy O- and N-type glycosylation. 
DNA/RNA 
Description 
In the genome, MUC16 is localized in 19p13.2 
chromosome and is coded by sequences present within  
 
approximatively 179 kb of genomic DNA. 
Transcription 
As per the present available information, there is a 
discrepancy regarding the total number of exons 
present in MUC16 genomic DNA. This discrepancy is 
due to the absence/presence of some of the genomic 
sequences (particularly for the repeat regions) in the 
available genomic databases. The terminal nine exons 
on both 5' and 3' ends code for the amino- and carboxy-
terminal domains of MUC16, respectively. At the same 
time, it has been proposed that five consecutive exons 
code for a single repeat unit (SRU) of the central 
tandem repeat domain. 
  
Shows the genomic organization of MUC16 gene. 
Protein 
 
Shows the structural organization of CA125/MUC16 protein. 
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Description 
MUC16 protein harbors a central tandem repeat region, 
N-terminal domain and carboxy terminal domain. The 
N-terminal domain has 12070 numbers of amino acids 
rich in serine/threonine residues and accounts for the 
major O-glycosylation known to be present in CA125. 
The MUC16 protein back bone is dominated by tandem 
repeat region, which has more than 60 repeat domains, 
each composed of 156 amino acids. Though all the 
individual repeat units are not similar, most of them 
occur more than once in the sequence. 
The repeat units are rich in serine, threonine and 
proline residues, which are typical for any mucins. 
Each repeat unit has some homology to the SEA (Sea-
urchin sperm protein, Enterokinase and Agrin) module, 
whose exact biological function is not known.  
The epitopes for known anti-CA125 antibodies (OC125 
and M11) are thought to be present on a small cysteine 
ring region present in the tandem-repeat region of 
MUC16. 
The carboxy-terminal domain has 284 aminoacids and 
can be divided into three different regions: extra 
cellular, transmembrane and cytoplasmic tail. The 
extracellular part of the carboxy-terminal domain has 
many N-glycosylation sites and some O-glycosyaltion 
sites. Several in silico analyses suggest a putative 
cleavage site in the extracellular part of carboxy-
terminal domain. The MUC16 cytoplasmic tail is 31 
amino acids long and has many possible 
phosphorylation sites. 
The phosphorylation of CA125 in WISH cells has been 
reported by labeling with 32PO43- and 
immunoprecipitaion analysis but the exact site of 
phosphorylation is yet to be mapped. Interestingly, 
CA125 contains a putative tyrosine phosphorylation 
site (RRKKEGY), which was first recognized in Src 
family protein. This sequence is conserved in the 
translated mouse EST (AK003577) that has homology 
with CA125/MUC16 at the C-terminal end. Recently, it 
has been shown that MUC16 cytoplasmic tail, which 
contains a polybasic aminoacid sequence, interacts with 
cytoskeleton through ERM (ezrin/radixin/moesin) 
actin-binding proteins. 
Expression 
The expression of MUC16 has been reported in human 
epithelia of conjunctiva, cornea, middle ear and trachea 
under normal physiological conditions. MUC16 is also 
expressed in ovarian carcinoma. 
Localisation 
It is a type I membrane-bound protein and due to 
cleavage gets secreted into the extracellular space. On 
the ocular surface, MUC16 is expressed on the tips of 
the microplicae of the ocular surface. 
Function 
MUC16 provides a disadhesive protective barrier to the 
ocular epithelial surface. Overexpression of 
CA125/MUC16 in ovarian cancer indicates its possible 
role in cancer pathogenesis. Studies have shown that 
CA125/MUC16 binds to mesothelin and galectin-1, 
which are overexpressed in ovarian cancer. It has also 
been shown that mesothelin-MUC16 interaction has 
significance in adhesion of ovarian cancer cells to 
mesothelial cells present on the inner wall of the 
peritoneum and on the surface of other abdominal 
organs. This cell to cell adhesion may help in ovarian 
cancer metastasis. It has been proposed that galectin-1 
bound to MUC16 may cause apoptosis of T cells, and 
thus help in the suppression of the host immunity. 
Homology 
Similar to mucin 16 of Pan troglodytes, Canis lupus 





Epithelial ovarian cancer is the most lethal 
gynaecologic malignancy in the United States and other 
parts of the world. In the United States, ovarian ccer 
accounts for approximately 22,000 new cases and 
16,000 deaths occurring every year. The epithelial 
ovarian carcinomas represent approximately 90% of all 
types of ovarian malignant neoplasms. Due to lack of 
specific signs and symptoms of this disease, coupled 
with lack of reliable screening strategies most patients 
are diagnosed in the advanced stage of the disease, 
resulting in low overall cure rates. Ovarian cancer 
patients are generally treated with surgical resection 
and subsequent platinum-based chemotherapy. 
Although, many patients initially respond well to 
chemotherapy, long term survival remains poor due to 
eventual tumor recurrence and emergence of drug-
resistant disease. Overall, the five year survival rate is 
45%. 
Prognosis 
Since the last 20 years, CA125/MUC16 has been used 
as a well-established marker for diagnosis of ovarian 
cancer. It is mostly overexpressed in serous type of 
ovarian cancers and less likely to be expressed in 
mucinous tumors. More than 80% of ovarian cancer 
patients have elevated CA125 level during their 
treatment period. It has been shown that the disease 
progression is associated with an increase in serum 
CA125 level, while a decline in serum CA125 level is 
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it has been shown that the trend of serum CA125 level  
during the first three courses of chemotherapy is a 
strong forecaster of re-examination findings in patients 
with ovarian carcinoma at the end of treatment. 
Interestingly, it has been shown that a normal CA125 
level by the end of second or third chemotherapy is 
strongly linked to the survival of patients in stage 3 or 
stage 4 conditions. Also, variations in the CA125 value 
even within the normal range carry useful information 
regarding prediction of time to treatment failure. 
Additionally, in patients in stage 1 cancers it has been 
suggested that CA125 elevations are not related to the 
tumor mass volume. Recently, the potential of 
CA125/MUC16 as a therapeutic target has been 
harnessed by using an armed human antibody (3A5) 
against MUC16 protein. 
Oncogenesis 
There is no experimental evidence in the scientific 
literature for a role of MUC16 in oncogenesis. 
However, MUC16 possesses many structural 
similarities with other membrane bound mucins, like 
MUC1 and MUC4, which are already shown to be 
functionally involved in different cancers. 
Transmembrane mucins are hypothesized to serve as 
sensors of the external environment and can transduce 
signals via the post-translational modifications of their 
cytoplasmic tail. Phosphorylation of MUC16 protein 
has already been reported. Though the exact interacting 
partner and the site of phosphorylation are unknown, 
the presence of potential phosphorylation sites in 
MUC16 cytoplasmic tail indicates the possible role f 
MUC16 in downstream signal transduction. Further, it 
has been shown that MUC16 interacts with galectin-1 
and mesothelin and these interactions may have a role 
in cancer progression. 
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